Intravenous Drug Incompatibilities in the Intensive Care Unit of a Tertiary Care Hospital in India: Are they Preventable?

Shanmugam Sriram¹, S. Aishwarya², Akhila Moithu², Akshaya Sebastian², Ajith Kumar²

Objective: The main aim of the study was to identify the physical and chemical incompatibilities among the drugs administered intravenously to patients admitted to the Intensive Care Unit (ICU) of a 1000 bedded hospital. The study also envisaged establishing pharmaceutical guidelines for the administration of incompatible medications. Methods: This prospective cross-sectional study was conducted from January to July 2018 in the ICU after getting approval from the Hospital Ethics Committee. A total of 104 medication charts were collected, and their data were analyzed. Compatibility of the selected drug with a second drug, when given together, was then analyzed using the Micromedex health-care series, Trissel’s handbook of injectable drugs, and Manufacturer’s product information. The pharmaceutical intervention was performed by preparing. The drug compatibility chart of selected drugs and the same was reported to the study department. Findings: Of 104 medication charts reviewed, 66 charts had incompatibility, accounting for 90 incompatibilities. Incompatibility between two intravenous (IV) bolus drugs constituted 68.8% with pantoprazole and ondansetron (85.4%) being the most frequent combination. Incompatibility between infusion-bolus was found to be 26.6%. Meropenem (infusion) and pantoprazole (bolus) constituted 16.6%. Incompatibility between two infusions in the same IV line was found to be 4.4%. A drug compatibility chart containing 19 selected drugs was prepared and submitted to the study department for their perusal. Conclusion: The current study showed that a significant number of drug incompatibilities occur in hospitalized critically ill patients in our tertiary care hospital. These incompatibilities could generally be prevented by adhering to proper medication administration techniques like flushing the line using compatible fluid or through a multi-lumen catheter or multiple IV access.

Keywords: Critically ill patients, drug-related problems, intensive care unit, intravenous drug incompatibilities

INTRODUCTION

The Intensive Care Unit (ICU) presents substantial patient safety challenges. In ICU, intravenous (IV) therapy is preferred over oral therapy. It is complex and error-prone hence requiring strategies to reduce the risk and complications. Infusion therapy is associated with a high risk of causing harm for patients. The administration of IV medications may be associated with undesirable effects, especially when administered in error. In a study by Tissot et al., it is reported that 18.6% of the total medication errors (MEs) belong to the category physicochemical incompatibility.

Drug incompatibility results from the simultaneous dilution and/or administration of two or more drugs that interfere with the therapeutic efficacy of the medications and patient safety, visually evidenced by

Address for correspondence:
Prof. Shanmugam Sriram,
E-mail: visitram@yahoo.com

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Sriram S, Aishwarya S, Moithu A, Sebastian A, Kumar A. Intravenous drug incompatibilities in the intensive care unit of a tertiary care hospital in India: Are they preventable? J Res Pharm Pract 2020;9:106-11.
change of solution color, precipitation, or turbidity. Physical reactions of drugs usually refer to either phase separation or precipitation due to a shift in the relation between ionization and nonionization and solubility. In chemical incompatibility, the medicine may undergo many chemical degradation pathways such as oxidation, reduction, hydrolysis, photolysis, or racemization. It can be perceived as turbidity, precipitation, and color changes. Therapeutic incompatibility may occur when two or more drugs are administered concurrently resulting in undesirable antagonistic or synergistic pharmacological activity.

These incompatibilities generally occurs between drugs and inappropriate diluents, two drugs: drug-drug incompatibility, when these are mixed in the same infusion line or the same IV container when these are administered one after the other within the same infusion line, drugs and adjutants such as stabilizer and solvent and drugs and materials of IV containers like polyvinyl chloride.

Probable mechanisms for these incompatibilities may be due to medicines that precipitate on dilution, precipitation of medications due to pH change on mixing, ionic reactions forming insoluble substances, and denaturation of biological molecules.

The extent and severity of the damage caused by incompatibility depend on the patient’s condition and the type of drug administered. Significant consequences are multiorgan failure, severe liver dysfunction, toxic shock, local embolus, myocarditis, respiratory difficulties, systemic allergic reactions, local allergic reactions, thrombosis, thrombophlebitis, phlebitis, and local redness.

Recent studies showed or recommended the following preventive strategies for preventing the IV drug incompatibilities as helpful: the usage of multiple lumen catheter, use of in-line infusion filters, separate IV infusion by time and place, flushing the IV line with a fluid compatible to the drug administered, and the color-coding system for drug pH.

The main objective of this study was to identify and document the physical and chemical incompatibilities among the drugs administered intravenously to patients admitted to the ICU of a tertiary care hospital in India and to establish pharmaceutical guidelines for the administration of incompatible drugs.

**METHODS**

This cross-sectional study was conducted at a 1000-bedded, private tertiary care multi-specialty teaching hospital located at Coimbatore. The study was conducted in the ICU of the hospital for a length of 6 months (January 2018–June 2018).

The study protocol was prepared and submitted to the Institutional Ethical Committee of the study hospital. The approval from the committee was obtained as a letter (SRH/EC.12-14/2017-18 dated 28th December 2017).

The inclusion criteria of our study were all inpatients of age 18 years and above, of either sex, getting admitted to the study site during the study, with length of stay equal to or longer than 24 h, prescriptions with 4 or more IV drugs and patients who were willing to participate were included in the study. We also excluded inpatients who were younger than 18 years, and who are not willing to participate in the study were excluded from the study.

Medication charts of 104 consecutive patients admitted in the ICU and treated with four or more IV drugs were analyzed. The patient baseline characteristics such as age, sex, the reason for hospitalization, comorbidities, laboratory investigations, diagnosis, and medication charts were obtained.

Compatibility of selected drugs with a second drug was analyzed using MICROMEDEX DRUG DATABASE which is available with the Department of Pharmacy Practice and TRISSEL’S HANDBOOK OF INJECTABLE DRUGS. A two-dimensional compatibility chart was then prepared to indicate the compatibility of a selected drug with a co-administered drug. Furthermore, the analysis of high alert medications, drug-drug interactions (DDI) was also analyzed.

**RESULTS**

The total number of patients included in the study and had fulfilled the inclusion criteria was 104 of which 72 (69.23%) were male and 32 (30.77%) were female. The result of gender categorization revealed that the overall study population was predominantly male population. The most dominant group was middle adulthood which accounts for 41.3% of the whole study population. The average age of the whole study population was found to be 58.03 ± 17.49 years.

The analysis showed that, out of 104 prescriptions, 66 prescriptions had incompatibility, summing to 90. IV incompatibility of continuous infusions and bolus doses when administered one after the other using the same line was 26.6% (n = 24) [Figure 1].

The analysis of drugs prescribed to the study population revealed that a minimum of 5 medicines and a
maximum of 24 drugs were found. The average number of medications prescribed was found to be 11.2 ± 3.8. Our analysis showed that the average ratio of IV drugs per patient were 7.74 ± 2.84. The majority of the study population has received antibiotics, anti-ulcer medications and anti-emetics.

Of 104 prescriptions analyzed, 42 prescriptions had DDIs. The results showed that there was a total of 65 DDIs of which 76.9% were major, and 16.9% were of moderate severity. Minor DDI constituted to 3.1% of the total DDI. One contraindicated pair was observed which is fluconazole and ondansetron combination which would result in QT interval prolongation.

Based on our observation and results, IV drug compatibility-alert card was prepared to enhance the rational use of IV medication and patient safety.

**Discussion**

Errors in the administration of IV drugs are numerous, with IV drug incompatibility being a significant problem. The current study provides information about the incompatibility of IV drugs administered in patients admitted to ICU.

In the study by Machotka et al., they have analyzed 50 medication charts within 12 months (January 2011–December 2011) comprising 54% females and 46% males, with a total of 318 IV drugs. In the present study, 63.4% of incompatibilities were found on analysis of 104 medication charts. Although a decreased prevalence of incompatibilities was found in the present study, this rate nevertheless remains high. This high rate of incompatibilities in the present study is correlated with multiple IV medications prescribed to critically ill patients.
The present study also analyzed 78 different medication regimes. The present study also analyzed 78 different IV drug regimes and found 26.9% of combinations tested exhibited drug incompatibility reactions. This difference in prevalence might be due to the diversity of morbidity profiles among the patients that might change the drug therapy regimen to be used. Most of the patients in the present study had comorbidities with either sustained hypertension (SHT) and diabetes mellitus or SHT alone of about 10.9%.

In this study, the frequency of intravenous incompatibilities between continuous infusion and bolus dose (26.6%) is depicted in Table 1 and the frequency of intravenous incompatibilities between continuous infusions at the same time (4.4%) is tabulated in Table 2 and the incompatibilities occurred between two bolus drugs (68.8%) is shown in Table 3. Among these, incompatibility between pantoprazole and ondansetron (58.8%) was commonly observed. Moraes et al. (2011) found that the most common drug incompatibility occurred between piperacillin-tazobactam and midazolam. In another study conducted by Marsilio et al., midazolam and cefepime were the most common drug incompatible pair. This between-studies difference might be due to the less prevalence of the incompatible pair piperacillin-tazobactam and midazolam (1.1%). Unlike the studies mentioned above, cefepime was not available in the drug regimes analyzed, consequently the difference in the results.

Pantoprazole was the most common drug involved in incompatibilities in the present study, followed by ondansetron and meropenem. The high frequencies of these drugs in incompatibilities might be relative because they are widely used in the ICU and are therefore present in numerous prescriptions.

In this study, pantoprazole was widely used for treating drug-induced gastrointestinal disturbances accounting for 9.3% of total IV medications administered. As this medication is available as a powder for solution, reconstitution must be done with D5W, Normal Saline or Ringer Lactate normal saline or ringer lactate (NS, or RL). The manufacture recommends the administration of pantoprazole through a dedicated line and avoids co-administration with other IV solutions.

Acute nature of patients in ICU necessitates the use of antibiotics frequently, and sometimes multiple antibiotic therapies need to be initiated. Nearly, 20%–40% of patients are documented to receive antimicrobial agents during hospitalization to treat and prevent nosocomial infections. In the present study, 24.5% of total IV medications were antibiotics with meropenem (5.2%), Piperacillin-Tazobactam (4.8%), and linezolid (3.2%) the frequently prescribed and the one to be involved in incompatibility.

Some medications are prone to show a higher risk of ME. These high-risk drugs can cause devastating consequences when misused. According to Tyynismaa et al., the most common human rights defenders (HRDs) were oxycodone (5%), enoxaparin (3%), and noradrenaline (3%). In the present study, of 24 different HRDs observed, enoxaparin (20.7%) occurred the most, followed by insulin (12.2%) and amikacin (10%). As these medications are at heightened risk for ME, their safe use in clinical practice must be ensured.

In the study by Rodrigues et al. conducted in ICU, observed 67% major and 74% moderate interactions in the prescriptions analyzed. They identified the interaction between dipyrone, and enoxaparin (35.8%) was the most prevalent. In our study, we noticed, 76.9% major and 16.9% moderate DDIs. Most of the significant drug interactions occurred with ondansetron comprising 38%. One contraindicated pair was observed between fluconazole and ondansetron resulting in QT interval prolongation, requiring electrocardiogram monitoring, though its clinical occurrence was not found in our study. The number of potential DDIs has a positive correlation with the number of prescribed drugs. Conceding the potential for higher risk of DDIs in ICU is essential in enhancing patient safety.

There were some limitations in our study, such as the analysis of incompatibilities involves the combination of only two drugs, unavailability of specific medication in the databases, inability to observe the clinical implication for patients. Although a pharmaceutical intervention in the form of the drug-incompatibility chart was developed, the adherence of health-care professionals to it was not evaluated.

Incompatibilities are an issue of concern, especially in patients admitted to the ICU because of the large

Table 3: Drug type frequency of intravenous incompatibilities between bolus doses at the same time

| Number | Bolus 1  | Bolus 2  | Effect                                      | n (% ) |
|--------|---------|---------|---------------------------------------------|--------|
| 1      | Ondansetron | Pantoprazole | Turbid precipitation + yellow discoloration | 53 (85.4) |
| 2      | Furosemide  | Pantoprazole | Haze/turbidity/particulate matter          | 3 (4.8)  |
| 3      | Ketorolac   | Pantoprazole | Haze, microparticulates, yellow discoloration | 3 (4.8)  |
| 4      | Dexamethasone | Pantoprazole | Precipitation                               | 2 (3.2)  |
| 5      | Fentanyl    | Pantoprazole | Haze and micro precipitation                | 1 (1.6)  |
Table 4: Drug-drug compatibility chart

| Drug-Drug compatibility chart | Acetaminophen | Acyclovir | Amikacin | Calcium Gluconate | Ceftriaxone | Clindamycin | Dexamethasone | Fentanyl | Fluconazole | Furosemide | Glycopyrrolate | Ketorolac | Levofloxacin | Meropenem | Metronidazole | Midazolam | Ondansetron | Pantoprazole | Piper/Tazo | Thiamine |
|-------------------------------|---------------|-----------|----------|-------------------|-------------|-------------|---------------|----------|-------------|------------|----------------|-----------|--------------|-----------|--------------|----------|------------|-------------|-----------|----------|
| Acetaminophen                 | -             | I         | NT       | NT                | C           | C           | C             | C        | NT          | NT         | NT             | I         | I            | NT        | NT           | NT       | NT         | NT          | NT        | NT       |
| Acyclovir                     | C             | -         | C        | C                 | C           | C           | C             | C        | C           | C          | NT             | C         | NT           | NT        | NT           | NT       | NT         | NT          | NT        | NT       |
| Amikacin                      | C             | C         | -        | NT                | C           | C           | C             | C        | NT          | NT         | NT             | C         | NT           | NT        | NT           | NT       | NT         | NT          | NT        | NT       |
| Calcium Gluconate             | NT            | C         | C        | -                 | NT          | C           | NT            | NT       | NT          | NT         | NT             | C         | NT           | NT        | NT           | NT       | NT         | NT          | NT        | NT       |
| Ceftriaxone                   | C             | C         | C        | -                 | NT          | C           | NT            | NT       | NT          | NT         | NT             | C         | NT           | NT        | NT           | NT       | NT         | NT          | NT        | NT       |
| Clindamycin                   | C             | C         | C        | -                 | NT          | C           | NT            | NT       | NT          | NT         | NT             | C         | NT           | NT        | NT           | NT       | NT         | NT          | NT        | NT       |
| Dexamethasone                 | C             | C         | C        | CV                | C           | C           | C             | C        | C           | C          | NT             | NT        | NT           | NT        | NT           | NT       | NT         | NT          | NT        | NT       |
| Fentanyl                      | C             | C         | C        | C                 | -           | C           | C             | C        | NT          | NT         | NT             | NT        | NT           | NT        | NT           | NT       | NT         | NT          | NT        | NT       |
| Fluconazole                   | NT            | C         | C        | CV                | CV          | CV          | C             | C        | NT          | NT         | NT             | NT        | NT           | NT        | NT           | NT       | NT         | NT          | NT        | NT       |
| Furosemide                    | NT            | C         | C        | CV                | CV          | CV          | C             | C        | NT          | NT         | NT             | NT        | NT           | NT        | NT           | NT       | NT         | NT          | NT        | NT       |
| Glycopyrrolate                | NT            | C         | C        | CV                | CV          | CV          | C             | C        | NT          | NT         | NT             | NT        | NT           | NT        | NT           | NT       | NT         | NT          | NT        | NT       |
| Ketorolac                     | C             | I         | C        | CV                | C           | CV          | C             | C        | C           | C          | NT             | NT        | NT           | NT        | NT           | NT       | NT         | NT          | NT        | NT       |
| Levofloxacin                  | NT            | NT        | NT       | -                 | NT          | NT          | NT            | NT       | NT          | NT         | NT             | NT        | NT           | NT        | NT           | NT       | NT         | NT          | NT        | NT       |
| Meropenem                     | NT            | NT        | NT       | -                 | NT          | NT          | NT            | NT       | NT          | NT         | NT             | NT        | NT           | NT        | NT           | NT       | NT         | NT          | NT        | NT       |
| Metronidazole                 | NT            | NT        | NT       | -                 | NT          | NT          | NT            | NT       | NT          | NT         | NT             | NT        | NT           | NT        | NT           | NT       | NT         | NT          | NT        | NT       |
| Midazolam                     | NT            | NT        | NT       | NT                | NT          | NT          | NT            | NT       | NT          | NT         | NT             | NT        | NT           | NT        | NT           | NT       | NT         | NT          | NT        | NT       |
| Ondansetron                   | NT            | NT        | NT       | NT                | NT          | NT          | NT            | NT       | NT          | NT         | NT             | NT        | NT           | NT        | NT           | NT       | NT         | NT          | NT        | NT       |
| Pantoprazole                  | NT            | NT        | NT       | NT                | NT          | NT          | NT            | NT       | NT          | NT         | NT             | NT        | NT           | NT        | NT           | NT       | NT         | NT          | NT        | NT       |
| Piper/Tazo                    | NT            | NT        | NT       | NT                | NT          | NT          | NT            | NT       | NT          | NT         | NT             | NT        | NT           | NT        | NT           | NT       | NT         | NT          | NT        | NT       |
| Thiamine                      | NT            | NT        | NT       | NT                | NT          | NT          | NT            | NT       | NT          | NT         | NT             | NT        | NT           | NT        | NT           | NT       | NT         | NT          | NT        | NT       |

NT=Not tested, CV=Caution variable, C=Compatible, I=Incompatible
number of parenteral drug applications. As there is a limited number of independent IV lines and the need for constant drug concentration, assessing their physicochemical compatibility is necessary to avoid negative consequences such as therapeutic failure, micro-embolisms, or even toxicity.

This study substantiated that a significant number of drug incompatibilities occur in ICU, clinical pharmacists have a crucial role in the detection and elimination of drug incompatibilities and other DRPs. The current study showed that a significant number of drug incompatibilities occur in hospitalized critically ill patients whom we studied. These incompatibilities could generally be prevented by adhering to proper medication administration techniques like flushing the line using compatible fluid, through a multi-lumen catheter, through multiple IV access, using in-line infusion filters, a spacing of medication or color-coding system. Pharmaceutical intervention by clinical pharmacists, in the form of drug compatibility chart [Table 4] for the common incompatible pair of drugs that was prepared and submitted, will enable the Physicians in the ICUs to be alert during the administration of such drugs.

AUTHORS’ CONTRIBUTION

Authors have made substantial contributions to conception and design, acquisition of data, analysis and interpretation of data and participated in drafting and revising.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Rothschild JM, Landrigan CP, Cronin JW, Kaushal R, Lockley SW, Burdick E, et al. The critical care safety study: The incidence and nature of adverse events and serious medical errors in intensive care. Crit Care Med 2005;33:1694-700.
2. Vijayakumar A, Sharon EV, Teena J, Nobil S, Nazeer I. A clinical study on drug-related problems associated with intravenous drug administration. J Basic Clin Pharm 2014;5:49-53.
3. Fekadu T, Tweledemedhin M, Esrael E, Asgedom SW. Prevalence of intravenous medication administration errors: A cross-sectional study. Integ Pharm Res Pract 2017;6:47-51.
4. Tissot E, Cornette C, Demoly P, Jacquet M, Barale F, Capellier G. Medication errors at the administration stage in an intensive care unit. Intensive Care Med 1999;25:353-9.
5. Secoli SR, Pérez-Esquivel E, de Las Heras-Matellán MJ, Vendrell-Bosh L, Ballarin-Alins E. [Incompatibilities in intravenous therapy: What can be done to prevent them?]. Enferm Clin 2009;19:349-53.
6. Braun B. Drug incompatibility risk prevention in infusion therapy. Eur J Clin Pharm 2004;59:815-7.
7. Murney P. To mix or not to mix – Compatibilities of parenteral drug solutions. Aust Prescr 2008;31:98-101.
8. Newton DW. Drug incompatibility chemistry. Am J Health Syst Pharm 2009;66:348-57.
9. Trissel LA. Handbook on Injectable Drugs. Bethesda, Maryland: American Society of Hospital Pharmacists, Inc.; 1994.
10. Lisa C. Compatibility of Commonly Used Intravenous Drugs. Pharmacy Practice News; 2011.
11. Rosenthal K. One size doesn’t fit all and other perils of IV administration. Nurs Made Incredibly Easy 2006;4:18-21.
12. Morris ME. Compatibility and stability of diazepam injection following dilution with intravenous fluids. Am J Hosp Pharm 1978;35:669-72.
13. Foinard A, Décaudin B, Barthélémy C, Debaene B, Odou P. The impact of multilumen infusion devices on the occurrence of known physical drug incompatibility: A controlled in vitro study. Anesth Analg 2013;116:101-6.
14. Collins JL, Lutz RJ. In vitro study of simultaneous infusion of incompatible drugs in multilumen catheters. Heart Lung 1991;20:271-7.
15. Jack T, Boehne M, Brent BE, Hoy L, Kōditz H, Wessel A, et al. In-line filtration reduces severe complications and length of stay on pediatric intensive care unit: A prospective, randomized, controlled trial. Intensive Care Med 2012;38:1008-16.
16. Perez M, Décaudin B, Foinard A, Barthélémy C, Debaene B, Lebuffe G, et al. Compatibility of medications during multi-infusion therapy: A controlled in vitro study on a multilumen infusion device. Anaesth Crit Care Pain Med 2015;34:83-8.
17. Machotka O, Manak J, Kubena A, Vlek J. Incidence of intravenous drug incompatibilities in intensive care units. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015;159:652-6.
18. Marsilio NR, Silva Dd, Bueno D. Drug incompatibilities in the adult intensive care unit of a university hospital. Rev Bras Ter Intensiva 2016;28:147-53.
19. Kahmann IV, Bürki R, Denzler U, Höfler A, Schmid B, Splisgardt H. Incompatibility reactions in the intensive care unit: Five years after the introduction of simple color coding. Anesth Analg 2003;5:409-12.
20. Moraes CG, Silva D, Bueno D. Analysis of intravenous drug incompatibilities at the adult intensive care unit of hospital das clínicas of Porto Alegre. Rev HCPA. 2011;31:31-8.
21. Bruno J. Intravenous Pantoprazole (Protonix®). Pharmacotherapy update. 2005:6.
22. Sarin MS, Vadivelan M, Bammigatti C. Antimicrobial therapy in the intensive care unit. Indian J Clin Pract 2013;23:601-9.
23. Jacoby TS. Association Between Consumption of Antimicrobials in Multidrug Resistance Intensive Care Center of Hospital Unversitáriobrasileiro, 2004-2006 [Dissertation]. Porto Alegre: Faculdade de Medicina da Universidade Federal do Rio Grande do Sul; 2008.
24. Institute for Safe Medication Practices. ISMP’s List of High Alert Medications in Community/Ambulatory Healthcare. Institute for Safe Medication Practices; 2010. Available from: https://ismp.org/communityRx/tools/ambulatoryhighalert.asp. [Last accessed on 2016 Nov 14].
25. Tynismaa L, Honkala A, Airaksinen M, Shermock K, Lehtonen L. Identifying high-alert medications in a university hospital by applying data from the medication error reporting system. Journal of Patient Safety 2019.
26. Rodrigues AT, Stahlschmidt R, Granja S, Pilger D, Felício AL, Mazzola PG. Prevalence of potential drug-drug interactions in the intensive care unit of a Brazilian teaching hospital. Brazilian Journal of Pharmaceutical Sciences 2017;53.